Evaluating only Larimar Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Larimar founded in Philadelphia targeting rare mitochondrial diseases including Friedreich's Ataxia.
FUNDING
IPO on Nasdaq raises $57M; stock opens at $15/share on promise of nomlabofusp efficacy.
PRODUCT LAUNCH
MOVE-FA pivotal Phase 2 trial fully enrolled with 100 patients; interim biomarker data looks promising.
SHUTDOWN
MOVE-FA fails primary neurological endpoint; stock crashes 80%, all programs halted, company winds down.
Full Analysis
Free · no account needed
Documented cause
Larimar Therapeutics, a Nasdaq-listed rare disease biotech, suffered a fatal blow in June 2024 when its lead drug nomlabofusp for Friedreich's Ataxia failed the pivotal Phase 2 MOVE-FA trial. CEO Carole Ben-Maimon announced the failure halted all development. The company had raised over $200M including a $57M IPO in 2020 but the primary endpoint — neurological function improvement — showed no statistical significance versus placebo, wiping out 80% of market cap in one day.
Lesson
“Single-asset rare disease biotechs must have interim data signals before committing to pivotal trials.”